Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.190
-0.005 (-0.42%)
At close: Jul 29, 2026, 4:00 PM EDT
1.172
-0.018 (-1.48%)
After-hours: Jul 29, 2026, 4:25 PM EDT
Spero Therapeutics Employees
Spero Therapeutics had 25 employees as of December 31, 2025. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
$2,447,440
Profits / Employee
$609,400
Market Cap
68.90M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 25 | -7 | -21.88% |
| Dec 31, 2024 | 32 | -14 | -30.43% |
| Dec 31, 2023 | 46 | 11 | 31.43% |
| Dec 31, 2022 | 35 | -111 | -76.03% |
| Dec 31, 2021 | 146 | 57 | 64.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| PolyPid | 75 |
| Pliant Therapeutics | 49 |
| Elicio Therapeutics | 33 |
| iBio, Inc. | 20 |
| LeonaBio | 19 |
| Atara Biotherapeutics | 13 |
SPRO News
- 2 days ago - Spero Therapeutics appoints Debra Jeske Zack as chief medical officer - TheFly
- 2 days ago - Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 15 days ago - Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
- 15 days ago - Spero Therapeutics secures $105M non-dilutive financing to develop SP001 - TheFly
- 15 days ago - Spero Therapeutics, Innovent Biologics enter license agreement for SP001 - TheFly
- 15 days ago - Spero Therapeutics, Innovent Biologics announce exclusive IBI355 license pact - TheFly
- 15 days ago - Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties - GlobeNewsWire
- 15 days ago - Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - PRNewsWire